Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Ninjin'yoeito for anorexia in advanced non-small-cell lung cancer
jRCTs041220102Phase 2Completed
- Sponsor
- Kracie Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ninjinyoeito in non-small cell lung cancer (NSCLC) and anorexia nervosa (AN), sponsored by Kracie Pharmaceutical. Primary endpoint: Change in anorexia score (SNAQ score). Started Dec 2022; status: completed.
02
Drugs
ninjinyoeito
03
Conditions
non-small cell lung cancer (NSCLC)anorexia nervosa (AN)
Beyond the preview
Go deeper on jRCTs041220102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220102.